Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket study

Forbes, 2019, A systematic review of international guidelines and recommendations for the genetic screening, diagnosis, genetic counseling, and treatment of BRCA-mutated breast cancer, Cancer Manag Res, 11, 2321, 10.2147/CMAR.S189627

Ford, 1994, Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium, Lancet, 343, 692, 10.1016/S0140-6736(94)91578-4

Foulkes, 2006, BRCA1 and BRCA2: chemosensitivity, treatment outcomes and prognosis, Fam Cancer, 5, 135, 10.1007/s10689-005-2832-5

Zimmer, 2018, Update on PARP inhibitors in breast cancer, Curr Treat Options Oncol, 19, 21, 10.1007/s11864-018-0540-2

Harlow, 2016, Lurbinectedin inactivates the Ewing sarcoma oncoprotein EWS-FLI1 by redistributing it within the nucleus, Cancer Res, 76, 6657, 10.1158/0008-5472.CAN-16-0568

Belgiovine, 2017, Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models, Br J Cancer, 117, 628, 10.1038/bjc.2017.205

Lima, 2016, Dual inhibition of ATR and ATM potentiates the activity of trabectedin and lurbinectedin by perturbing the DNA damage response and homologous recombination repair, Oncotarget, 7, 25885, 10.18632/oncotarget.8292

Romano, 2013, Comparison of in vitro and in vivo biological effects of trabectedin, lurbinectedin (PM01183) and Zalypsis(R) (PM00104), Int J Cancer, 133, 2024, 10.1002/ijc.28213

Santamaria Nuñez, 2016, Lurbinectedin specifically triggers the degradation of phosphorylated RNA polymerase II and the formation of DNA breaks in cancer cells, Mol Cancer Ther, 15, 2399, 10.1158/1535-7163.MCT-16-0172

Bhatia, 2014, BRCA2 prevents R-loop accumulation and associates with TREX-2 mRNA export factor PCID2, Nature, 511, 362, 10.1038/nature13374

Huertas, 2003, Cotranscriptionally formed DNA:RNA hybrids mediate transcription elongation impairment and transcription-associated recombination, Mol Cell, 12, 711, 10.1016/j.molcel.2003.08.010

Trigo, 2020, Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial, Lancet Oncol, 21, 645, 10.1016/S1470-2045(20)30068-1

Singh, 2021, FDA approval summary: lurbinectedin for the treatment of metastatic small cell lung cancer, Clin Cancer Res, 27, 2378, 10.1158/1078-0432.CCR-20-3901

Cruz, 2018, Multicenter phase II study of lurbinectedin in BRCA-mutated and unselected metastatic advanced breast cancer and biomarker assessment substudy, J Clin Oncol, 36, 3134, 10.1200/JCO.2018.78.6558

Eisenhauer, 2009, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur J Cancer, 45, 228, 10.1016/j.ejca.2008.10.026

Ghouadni, 2017, Higher antitumor activity of trabectedin in germline BRCA2 carriers with advanced breast cancer as compared to BRCA1 carriers: a subset analysis of a dedicated phase II trial, Breast, 34, 18, 10.1016/j.breast.2017.04.006

Poveda, 2017, Phase II randomized study of PM01183 versus topotecan in patients with platinum-resistant/refractory advanced ovarian cancer, Ann Oncol, 28, 1280, 10.1093/annonc/mdx111

Gaillard, 2021, Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: a multicenter, randomized, controlled, open-label phase 3 study (CORAIL), Gynecol Oncol, 163, 237, 10.1016/j.ygyno.2021.08.032

Subbiah, 2022, Antitumor activity of lurbinectedin, a selective inhibitor of oncogene transcription, in patients with relapsed Ewing sarcoma: results of a basket phase II study, Clin Cancer Res, 28, 2762, 10.1158/1078-0432.CCR-22-0696